# Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma

> **NCT00895960** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Glioblastoma
- CNS Disease
- Brain Diseases

## Interventions

- **DRUG:** Dasatinib
- **RADIATION:** RT (Radiotherapy)
- **DRUG:** TMZ (Temozolomide)

## Key facts

- **NCT ID:** NCT00895960
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05-07
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Sponsor withdrew support; Study did not progress to Phase II.
- **Last updated:** 2018-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00895960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00895960, "Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00895960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*